Medroxyprogesterone
From Wikipedia, the free encyclopedia
|
Medroxyprogesterone
|
|
| Systematic (IUPAC) name | |
| 17-acetyl-17-hydroxy- 6,10,13-trimethyl- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | G03 G03DA02, L02AB02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C22H32O3 |
| Mol. mass | 344.488 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 90% |
| Metabolism | ? |
| Half life | 50 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Medroxyprogesterone is a progestin, and is commonly a component of hormonal contraceptives. It can be used in the treatment of endometriosis, abnormal menstrual bleeding or amenorrhea.[1][2] Possible side effects include weight gain, depression, and irregular menses or amenorrhea.